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Hyperlipidemia is a risk factor for osteonecrosis in
children and young adults with acute lymphoblastic
leukemia
Steroid-induced osteonecrosis (ON) is a serious compli-
cation of anti-leukemic therapy in children and young
adults with acute lymphoblastic leukemia (ALL). Patients
with ON experience severe pain and reduced mobility,
ultimately leading to surgery with arthroplasty. Survival
of ALL has increased to 90%, necessitating improved
treatment to reduce the late effects.1,2 However, as the
pathogenesis of ON is poorly understood, prevention is
challenging. Hyperlipidemia is seemingly a key risk factor
for ON, but only few studies have addressed this issue,
and the results are inconclusive.3,4 Therefore, to elucidate
the role of hyperlipidemia in ON, we studied lipid alter-
ations during ALL therapy. Our findings could lead to
future stratified interventions specifically targeting
patients at high risk of developing ON.
We included all patients in Denmark, aged 5–45 years
at ALL diagnosis, treated with the Nordic Society of
Paediatric Haematology and Oncology (NOPHO)
ALL2008 protocol (n=182). Registration of symptomatic
ON was prospectively reported.5 All patients were fol-
lowed from diagnosis of ALL until diagnosis of ON,
relapse, second malignant neoplasia (SMN) or end of fol-
low up, August 27, 2015, whichever came first. Patients
were stratified into standard-risk (SR), intermediate-risk
(IR) and high-risk therapy. Therapy lasted 2.5 years and is
described in detail elsewhere5–7 (Online Supplementary
Material). Retrospectively, we analyzed non-fasting
triglycerides (TG), total cholesterol (CH), high-density
lipoprotein (HDL), and low-density lipoprotein (LDL) on
plasma samples taken at ALL diagnosis (i.e., baseline) and
during therapy. Lipid levels were routinely analyzed for
clinical purposes throughout the therapy, at two treat-
ment centers (Online Supplementary Material).
Briefly, baseline characteristics were analyzed by sim-
ple Cox proportional hazard regression. Baseline lipids
were analyzed by multiple Cox regression adjusted for
sex and age at diagnosis. For each lipid, we calculated the
running mean with standard error (SE) Day 30–250 after
ALL diagnosis. If ON or competing events (relapse or
SMN) occurred before Day 250, the patient’s subsequent
lipid-measurements were excluded. For SR/IR patients,
we predefined two treatment intervals: ConsASP Day 50–
89, where patients received pegylated asparaginase (PEG-
ASP) but not dexamethasone, and DIASP+DEXA Day 90–
130, including both PEG-ASP and dexamethasone. In
these intervals we used peak values of TG, CH and LDL
and trough values of HDL. Subsequently, groups with
high/low levels of peak/trough lipids were defined based
on cut-off estimated by Youden’s index on the receiver
operating characteristic (ROC) curve. Peak/trough levels
were analyzed using multiple Cox regression adjusted for
sex and age at diagnosis. The cumulative incidences
between groups were compared using Gray’s test. Mean
lipid-levels were analyzed as time-dependent continuous
parameters Day 0–250 in a Cox regression with delayed
entry of patients at the first lipid measurement. We recal-
culated the weighted means every time a patient experi-
enced an event. The weights were the intervals between
the two measurements, maximum seven days. Analyses
were adjusted for sex and age at ALL diagnosis, and strat-
ified by risk group. In all Cox analyses, competing events
were censored. ON-specific hazard ratios (HR) were cal-
culated per mmol/L (Online Supplementary Material).
We included 112 patients diagnosed with ALL from
July 2008 to December 2014. Patients were excluded due
to lack of consent (n=35), non-protocol treatment (n=11),
stem cell transplantation (n=14), death during treatment
(n=8), and no available lipid-measurements (n=2) (Online
Supplementary Figure S1). Median follow up was 3.2
years. Of the patients, 3 experienced ALL relapse and one
developed SMN. Symptomatic ON was diagnosed in 22
patients. Time from ALL diagnosis to ON diagnosis
ranged from 153–1362 days (median: 654), using date
when ON was first confirmed by radiological imaging.
The overall cumulative incidence of ON was 22.9% (95%
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Table 1. Baseline and peak/trough lipid levels for standard-risk and intermediate-risk patients. 
Lipid No. of patients ON-specific HR b) P a)
(ON/non-ON) (95% CI)
Baseline
TG mmol/L 9/30 1.26 (0.65–2.42) 0.493
CH mmol/L 9/30 1.13 (0.57–2.24) 0.719
LDL mmol/L 9/30 1.00 (0.43–2.29) 0.993
HDL mmol/L 9/30 0.52 (0.03–8.18) 0.645
Peak/trough levels in ConsASP
peak-TG mmol/L 16/61 1.08 (0.99–1.17) 0.062
peak-CH mmol/L 15/60 0.99 (0.77–1.28) 0.936
peak-LDL mmol/L 14/58 0.63 (0.32–1.23) 0.176
trough-HDL mmol/L 14/58 1.96 (0.38–10.1) 0.421
Peak/trough levels in DIASP+DEXA
peak-TG mmol/L 18/62 1.02 (1.00–1.04) 0.025*
peak-CH mmol/L 18/61 1.12 (1.04–1.21) 0.003*
peak-LDL mmol/L 17/57 0.98 (0.76–1.25) 0.860
trough-HDL mmol/L 17/57 0.59 (0.21–1.70) 0.331
ON: osteonecrosis; CI: confidence interval; HR: hazard ratio; TG: triglyceride; CH: cholesterol; LDL: low-density lipoprotein; HDL: high-density lipoprotein; ConsASP: Day 50–
89; DIASP+DEXA: Day 90–130 a) Multiple Cox regression, adjusted for age at ALL diagnosis and sex. b) ON-specific HR was calculated per mmol/L. *indicates levels below
0.05 
confidence interval (CI): 13.9–30.8). Age at ALL diagnosis
for ON patients ranged 5.2–37 years, which defined the
age eligibility criterion by the youngest patient. ON
patients were graded according to the Ponte di Legno
toxicity working group grade 4 (n=12) and grade 2-3
(n=10)2, and 10 patients underwent surgery. At time of
ON diagnosis, 10 patients had multiple joints affected, all
with involvement of hip and/or knee. Eleven patients had
a single joint affected, including hip (n=5), knee (n=1),
ankle (n=2), shoulder (n=2), and elbow (n=1).
Median age at ALL diagnosis was 12.7 years and 10.9
years for ON patients and non-ON patients, respectively.
ON was diagnosed in 10 female patients and 12 male
patients, and treated according to SR (n=5), IR (n=15) and
high-risk (n=2) (Online Supplementary Table S1). We found
no association between ON and age at diagnosis
(P=0.85), sex (P=0.72), risk group (P=0.40), white blood
cell count (P=0.57), steroid during induction (P=0.33) or
body mass index at diagnosis (P>0.99). 
Baseline lipid levels showed no association with ON-
specific HR (Table 1). Lipid alterations for treatment Day
30–250 are illustrated for TG, CH, HDL and LDL for all
ON patients and non-ON patients (Figure 1A-D). TG and
CH increased during therapy, noticeably greater for ON
patients (Figure 1A-B). The peak level was observed
around Days 100 and 120 for TG and CH, respectively.
We observed a decrease of HDL during therapy, margin-
ally greater in ON patients (Figure 1C). The lowest HDL
levels were observed around Day 90. LDL alterations
were minimal, illustrating no difference between groups
(Figure 1D).
Peak/trough lipid levels were analyzed in the prede-
fined treatment interval, i.e., ConsASP and DIASP+DEXA
(Table 1). In DIASP+DEXA, we found significantly
increased ON-specific HR with higher peak-TG
(HR=1.02, P=0.025) and higher peak-CH (HR=1.12,
P=0.003). In ConsASP, we similarly found increased ON-
specific HR with higher peak-TG, though non-significant
(HR=1.08, P=0.062), but no significant association for
peak-CH (HR=0.99, P=0.936). For peak-LDL and trough-
HDL, we found no significant association with ON in
either interval. 
Subsequently, we estimated the cut-off at 18.1 mmol/L
for peak-TG in DIASP+DEXA (ROC: area under the curve
(AUC)=0.653, sensitivity=0.50, specificity=0.85). Patients
were grouped into high/low peak-TG based on the cut-
off (Online Supplementary Figure S2). The 3-year cumula-
tive ON incidence for patients with high peak-TG was
significantly higher (54.0%) than for patients with low
peak-TG (16.8%, P<0.001) (Figure 2A). The cut-off esti-
mation for peak-CH in DIASP+DEXA was 7.7 mmol/L
(ROC: AUC=0.696, sensitivity=0.72, specificity=0.69).
Using this cut-off, we found a significantly higher 3-year
cumulative ON incidence for patients with high peak-CH
(45.3%) compared with patients with low peak-CH
(12.2%, P=0.0014) (Figure 2B). Analyses were made for
all peak/trough lipids in both intervals, but for the rest
ROC showed AUC<0.60 and sensitivity or specificity
below 0.5, indicating poor estimation of the cut-off value
(results not shown). In DIASP+DEXA, 13/18 (72%) ON
patients had either peak-TG or peak-CH above the cut-
off and 9/18 (50%) had simultaneous elevation.
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Figure 1. Running means of lipid levels. The running means of A. levels of triglyceride, B. cholesterol, C. high-density lipoprotein (HDL) and D. low-density lipopro-
tein (LDL) in mmol/L, Day 30–250 after diagnosis of acute lymphoblastic leukemia (ALL) for osteonecrosis patients (filled lines) and non-osteonecrosis patients
(dashed lines). The shaded areas show the standard error for each group. Lipid levels are shown in absolute values on a logarithmic scale. The vertical dotted
lines indicate treatment intervals in consolidation Day 50–89 (ConsASP) and delayed intensification Day 90–130 (DIASP+DEXA).
A B
C D
We analyzed prolonged exposure to hyperlipidemia
Day 0–250. We found significantly higher ON-specific
HR per mmol/L for increased TG levels (HR=1.08,
P=0.038), likewise for CH levels (HR=1.26, P=0.039). We
also found a tendency of an inverse association between
higher HDL and ON (HR=0.22, P=0.053). Prolonged
exposure of LDL was not associated with ON (HR=1.23,
P=0.495).
In this population-based study, hyperlipidemia
increased the risk of developing ON. Adolescents are at
increased risk of both hyperlipidemia8 and ON.1 We
found cut-off levels for both peak-TG and peak-CH, iden-
tifying groups of patients with exceptionally high inci-
dence of ON. This suggests that, apart from age, peak-TG
and peak-CH are important predictors. Additionally, we
found that prolonged exposure to hypertriglyceridemia
or hypercholesterolemia was associated with increased
risk of ON, demonstrating that hyperlipidemia during
longer periods could induce ON. To our knowledge, no
other human studies have investigated similar associa-
tions; we suggest validation in other cohorts. 
The pathogenesis behind hyperlipidemia-induced ON
is poorly understood. A possible mechanism is increased
blood viscosity leading to reduced blood flow.9
Furthermore, Powell et al. proposed that “compartment
syndrome” in the bone could induce ON10. Increased
intraosseous pressure caused by hyperlipidemia, through
deposition of fat in the intramedullary tissue11 and
enlargements of fat cells in the bone marrow cavity,12
might induce this “compartment syndrome state”. 
Kawedia et al. reported a link between ON and hyper-
cholesterolemia.3 Conversely, no human studies have
found that hypertriglyceridemia induces ON.3,4 Compared
with similar phases in previous studies, the NOPHO
ALL2008 protocol uses intense dexamethasone therapy
for SR/IR patients, possibly influencing the severity of
lipid alterations.3,4 Additional differences between studies
could occur due to i) predefined/estimated cut-off levels,4
ii) capturing of the actual peak levels, iii) ethnicity and
host-specific genetics,13 and iv) fasting/non-fasting lipid
measurements. 
ON is primarily induced by glucocorticosteroids.14
However, due to pharmacokinetic interaction, lipid alter-
ations are the most pronounced during simultaneous
PEG-ASP and dexamethasone therapy.8,15 Therefore, tim-
ing and severity of hyperlipidemia seemingly depend on
scheduling of both dexamethasone and PEG-ASP. We
speculate that PEG-ASP could play a larger role in the
pathogenesis of ON than previously assumed. The
NOPHO ALL2008 protocol includes a randomized trial
investigating continuous vs. non-continuous PEG-ASP
treatment. Asparaginase-related toxicities will be ana-
lyzed, including the effect on risk of ON. Moreover, we
propose interventional studies, using antihyperlipidemic
drugs, physical activity and diet, targeted toward reduc-
ing TG and CH in hyperlipidemic children and young
adults.  
In conclusion, we find hypertriglyceridemia and hyper-
cholesterolemia to be important risk factors for develop-
ing ON. Interventional studies are needed to elucidate
whether lowering TG and CH during combined PEG-ASP
and dexamethasone therapy can reduce the risk of ON.
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Figure 2. Cumulative incidence of osteonecrosis. The cumulative incidence of osteonecrosis grouping patients according to a cut-off level during DIASP+DEXA of
(A) 18.1 mmol/L for peak-triglyceride, and (B) 7.7 mmol/L for peak-cholesterol. The follow up starts at the end of the interval DIASP+DEXA (Day 130 after diagnosis
of acute lymphoblastic leukemia). P-values are from Gray’s test comparing the cumulative incidences. 
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